PDS Biotechnology (PDSB)

• Market cap: $61.4M
• 1 day: -1.80%
• 5 days: -16.33%
• 1 month: -24.42%
• 3 months: -47.60%
• 6 months: -42.66%
• Year to date: -68.16%
• 1 year: -68.03%
• 5 years: -29.61%
• 10 years: -87.33%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Employees: 25

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

386% more call options, than puts

Call options by funds: $1.35M | Put options by funds: $278K

1% more capital invested

Capital invested by funds: $16.3M [Q2] → $16.5M (+$219K) [Q3]

3.42% less ownership

Funds ownership: 15.17% [Q2] → 11.75% (-3.42%) [Q3]

26% less funds holding

Funds holding: 76 [Q2] → 56 (-20) [Q3]

62% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 21

74% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 27

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $7 327% upside
• Avg. target: $14 754% upside
• High target: $21 1,180% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 82 / 386 met price target	1,180% upside $21	Buy Reiterated	18 Dec 2024
B. Riley Securities Kalpit Patel 33% 1-year accuracy 3 / 9 met price target	327% upside $7	Buy Maintained	25 Nov 2024